Loading…
Creative Medical Technology Holdings Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CELZ.
▼ -98.6% over 5Y.
today you would have $13.73▼ -98.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.96 | $2.31 | $4.61 | $3.81 | |
| P/S | 535.4x | 1207.6x | 367.2x | 703.6x | 60.5x |
| P/B | 0.6x | 1.0x | 0.6x | 0.6x | 0.3x |
| EPS | -$2.52 | -$3.71 | -$3.76 | -$9.28 | |
| Profit margin | -54340.22% | -99916.80% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NVNOenVVeno Medical Corp | $10.75 | — | 0.4x | — | -58.53% | $7.47M |
| INMInMed Pharmaceuticals Inc. | $1.38 | — | 0.7x | — | -112.65% | $7.37M |
| CANFCan-Fite BioPharma Ltd. | $3.40 | — | 0.8x | — | -178.24% | $7.28M |
| ENSCEnsysce Biosciences, Inc. | $0.40 |
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Company description provided by Yahoo Finance.
| -49940.74% |
| -58739.71% |
| -11449.26% |
| ROE | -71.86% | -79.78% | -86.63% | -51.11% | -63.94% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -1295.09% |
| $7.78M |
| ITOCiTonic Holdings Ltd | $0.32 | — | 0.9x | — | -71.25% | $7.83M |
| SKYESkye Bioscience, Inc. | $1.78 | — | — | — | -233.87% | $7.86M |